Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T21:38:52.168Z.
Consensus retrieved: 2026-10-06T17:32:28.841Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:38:52.168Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 97452f2638ad5d60f1716ef7360feea6a822b872a50cf44a9ba771f9e60b5836
Forward PE Ratio (N/A) = Dated Quote Price ($166.97) / Consensus Forward EPS ($-1.38)
FORWARD PE RATIO
N/A
Twist Bioscience Corporation
Market Cap
$10.40B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Twist Bioscience Corporation (TWST) | $10.40B | N/A |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 15.28 |
| 10x Genomics, Inc. (TXG)vs › | $10.24B | N/A |
| Molina Healthcare, Inc. (MOH)vs › | $10.19B | N/A |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 12.55 |
| Universal Health Services, Inc. (UHS)vs › | $10.72B | 7.84 |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 22.08 |
| BioMarin Pharmaceutical Inc. (BMRN)vs › | $10.87B | N/A |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 37.84 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2027-09-30
At the dated quote price of $166.97, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2027-09-30 | $-1.38 | $-1.43 – $-1.27 | 5 | n/m |
| 2028-09-30 | $-0.98 | $-1.52 – $-0.55 | 7 | n/m |
| 2029-09-30 | $-0.17 | $-0.63 – $0.30 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
